

# The Commercial Use of Biodiversity

Access to Genetic Resources  
and Benefit-Sharing

*Kerry ten Kate and Sarah A Laird*

**EARTHSCAN**

Earthscan Publications Ltd, London

# Contents

List of Boxes, Figures and Tables ix

Acronyms and Abbreviations xii

Foreword xv

Acknowledgements xvii

## 1 Introduction 1

- 1.1 The market for genetic resources 1
- 1.2 The economic value of biological diversity 3
- 1.3 The CBD and national laws on access and benefit-sharing 3
- 1.4 The actors 4
  - 1.4.1 The private sector 5
  - 1.4.2 The public sector 5
  - 1.4.3 Intermediaries 5
  - 1.4.4 Communities 6
- 1.5 The different perspectives 7
  - 1.5.1 The companies' argument 7
  - 1.5.2 The source countries' argument 8
- 1.6 The sectors 9
  - 1.6.1 Market size and growth 9
  - 1.6.2 Research 10
  - 1.6.3 Cost and time to develop a product 10
  - 1.6.4 Social, environmental and ethical issues 10
- 1.7 The commercial use of biodiversity: about this book 10
  - 1.7.1 Content of the book 11
- 1.8 Conclusion 12

## 2 Regulating Access to Genetic Resources and Benefit-Sharing: the Legal Aspects 13

- 2.1 Introduction to the CBD and national law related to access to genetic resources 13
  - 2.1.1 The CBD: an overview 13
  - 2.1.2 The CBD process 14
  - 2.1.3 Access to genetic resources and benefit-sharing in the CBD 15
  - 2.1.4 National and regional regulation of access to genetic resources and benefit-sharing 16
- 2.2 The scope and requirements of national and regional law on access to genetic resources and benefit-sharing 17
  - 2.2.1 Scope 17
  - 2.2.2 Mutually agreed terms 22
  - 2.2.3 Prior informed consent 27
- 2.3 Conclusions for individuals seeking access to genetic resources and benefit-sharing 32

## 3 Natural Products and the Pharmaceutical Industry 34

- 3.1 Introduction 34
- 3.2 The pharmaceutical industry 34
  - 3.2.1 Global markets 34
  - 3.2.2 Structure of the industry 35
- 3.3 The role and value of natural product-derived drugs 40
  - 3.3.1 Plants 43
  - 3.3.2 Microbial sources 43
  - 3.3.3 Marine organisms 44
  - 3.3.4 Insects 44
  - 3.3.5 Animal genetic resources 44
  - 3.3.6 Human genetic resources 45
- 3.4. Pharmaceutical industry investment in research and development 45
  - 3.4.1 An overview of pharmaceutical industry research and development expenditures 45
  - 3.4.2 Investment and time to discover and develop a new drug 47
- 3.5. Pharmaceutical drug discovery and development 49
  - 3.5.1 Discovery 49
  - 3.5.2 Development 53
  - 3.5.3 Trends in pharmaceutical research and development and the role of natural products 55
  - 3.5.4 Conclusions 57
- 3.6 The acquisition of natural product samples 58
  - 3.6.1 Who collects genetic resources? 58
  - 3.6.2 Sourcing samples from libraries and *ex situ* collections 59
  - 3.6.3 The scale of acquisition programmes 59
  - 3.6.4 Types of material acquired 60
  - 3.6.5 Criteria for sample collection 60
  - 3.6.6 The ethnobotanical approach to drug discovery 61
  - 3.6.7 Representation of geographic diversity in collections 62
- 3.7 Benefit-sharing 63
  - 3.7.1 Monetary benefits 64
  - 3.7.2 Non-monetary benefits 68
  - 3.7.3 Public benefits 75
- 3.8 Conclusions 76

## 4 The Botanical Medicine Industry 78

- 4.1 Introduction 78
- 4.2 The botanical medicine industry 79
  - 4.2.1 Global markets 79
  - 4.2.2 Botanical medicine products 80

## THE COMMERCIAL USE OF BIODIVERSITY

- 4.3 The structure of the botanical medicine industry 83
  - 4.3.1 Supply companies 84
  - 4.3.2 Manufacturing and marketing companies 86
  - 4.3.3 Consumer sales 86
- 4.4 Market trends 88
- 4.5 Scientific and technological trends 92
  - 4.5.1 Developing a new product 92
  - 4.5.2 Identification, extraction and standardisation 94
- 4.6 Regulatory trends 96
- 4.7 Nutraceuticals 97
  - 4.7.1 US regulatory environment 98
- 4.8 Raw material supplies 99
  - 4.8.1 'Boom/bust' cycles 100
  - 4.8.2 Major raw material exporting and importing countries 101
  - 4.8.3 Wild versus cultivated sources 101
  - 4.8.4 Conservation and wise management 102
- 4.9 Case study: exploding international demand for a species with widespread traditional use: the case of kava (*Piper methysticum*) 104
- 4.10 Practices in benefit-sharing 108
  - 4.10.1 Monetary benefits 108
  - 4.10.2 Non-monetary benefits 108
- 4.11 Case study: The development of a benefit-sharing partnership in Vietnam: *Panax vietnamensis* – a 'new' ginseng 112
- 4.12 Conclusion 115

### 5 The Development of Major Crops by the Seed Industry 117

- 5.1 Introduction 117
  - 5.1.1 Policy context 118
  - 5.1.2 The roles of actors and markets 122
  - 5.1.3 The development of a new variety 126
- 5.2 Regulations relevant to the release of new agricultural crop varieties on to the market 129
  - 5.2.1 Phytosanitary measures 129
  - 5.2.2 Seed certification and labelling 129
  - 5.2.3 Intellectual property rights 130
  - 5.2.4 The release and marketing of GMOs 130
  - 5.2.5 The implications for access of seed certification systems, the regulation of GMOs, PS measures and IPRs 131
- 5.3 Access to genetic resources 131
  - 5.3.1 Who needs access to genetic resources? 131
  - 5.3.2 How do breeders select materials for use in breeding efforts? 133
  - 5.3.3 From where and from whom do breeders obtain their material? 135
- 5.4 What kind of material do breeders want? 137
  - 5.4.1 The demand for access to landraces and wild relatives for seed breeding 137

- 5.4.2 The demand for access to 'foreign' or 'exotic' material in crop breeding 139
- 5.4.3 Will the demand for access to primitive and exotic materials grow in the future? 141
- 5.4.4 The demand for access to improved material in seed breeding 141
- 5.4.5 Conclusions on access 142
- 5.5 Benefit-sharing 142
  - 5.5.1 Introduction 142
  - 5.5.2 Monetary benefits 144
  - 5.5.3 Non-monetary benefits 147
  - 5.5.4 IR64: a case study 149
- 5.6 Conclusions and recommendations 154
  - 5.6.1 Conclusions 154
  - 5.6.2 Recommendations 156

## 6 Horticulture

- 6.1 Introduction 158
  - 6.1.1 The definition of 'horticulture' and the scope of this chapter 158
  - 6.1.2 The actors and their role in the development of new ornamental varieties 162
  - 6.1.3 The role of horticulture companies in breeding new ornamental varieties 164
- 6.2 Access to genetic resources 171
  - 6.2.1 Demand for access to new materials 171
  - 6.2.2 Sources of material 172
- 6.3 Benefit-sharing 176
  - 6.3.1 Monetary benefits 176
  - 6.3.2 Non-monetary benefits 179
- 6.4 Case studies 180
  - 6.4.1 Orchid-breeding and registration 180
  - 6.4.2 The Pipa Horticultural Company Ltd 184
- 6.5 Conclusions 186

## 7 Crop Protection 188

- 7.1 Introduction 188
  - 7.1.1 The roles of actors and markets 189
  - 7.1.2 Crop protection products based on or derived from genetic resources 193
  - 7.1.3 The process of developing a new crop protection product 194
- 7.2 Access to genetic resources 210
  - 7.2.1 Which organisations require access to genetic resources? 210
  - 7.2.2 From where are genetic resources obtained? 210
  - 7.2.3 What kind of genetic resources are in demand? 211
  - 7.2.4 How are genetic resources selected for research? 213
  - 7.2.5 Future demand for access to genetic resources 214
- 7.3 Benefit-sharing 215
  - 7.3.1 Monetary benefits 215
  - 7.3.2 Non-monetary benefits 215
- 7.4 Case studies 217

7.4.1	Benefit-sharing by the International Locust Control Programme, <i>Lutte Biologique contre les Locustes et les Sauteriaux</i> (LUBILOSA) 217
7.4.2	The Latin American International Cooperative Biodiversity Group (ICBG) 224
7.5	Conclusions 225
<b>8</b>	<b>Biotechnology in Fields other than Healthcare and Agriculture 228</b>
8.1	Introduction 228
8.1.1	Introduction to biotechnology products and processes 229
8.1.2	The actors 229
8.1.3	Quantifying markets 232
8.1.4	Some important categories of biotechnology products 234
8.1.5	The research and development process 238
8.1.6	The regulatory process 239
8.2	Access to genetic resources 241
8.2.1	Who collects genetic resources for biotechnology research and development? 241
8.2.2	<i>Ex situ</i> collections 242
8.2.3	Acquisition of materials from other organisations 244
8.2.4	How are genetic resources selected for research and development? 245
8.2.5	The nature of genetic resources sought 247
8.2.6	Resupply 248
8.2.7	Choice of suppliers and collaborators 248
8.3	Benefit-sharing 250
8.3.1	Monetary benefits 250
8.3.2	Non-monetary benefits 252
8.4	Case studies 253
8.4.1	The Diversa/INBio Agreement 253
8.4.2	New England Biolabs 257
8.5	Conclusions 260
<b>9</b>	<b>The Natural Personal Care and Cosmetics Industry 262</b>
9.1	Introduction 262
9.2	The natural personal care and cosmetics market 263
9.2.1	Definition of category 263
9.2.2	Global markets for personal care and cosmetic products 263
9.2.3	Types of markets and outlets for products 264
9.2.4	The natural component of the personal care and cosmetics market 264
9.2.5	Structure of the industry 265
9.3	What is 'natural'? 266
9.4	Trends that impact demand for natural personal care and cosmetic products 268
9.5	Scientific and technological trends 270
9.5.1	Product and ingredient trends 271
9.5.2	The use of traditional knowledge 272

9.5.3	The acquisition of natural product samples 274
9.6	Sourcing raw materials for manufacture 274
9.7	Regulatory environment 275
9.8	Demand for access to 'new' species 276
9.9	Benefit-sharing 277
9.9.1	Monetary benefits 277
9.9.2	Non-monetary benefits 278
9.9.3	Benefit-sharing conclusions 281
9.10	Case studies 281
9.10.1	The production and marketing of a species in the 'public domain': the Yawanawa and Aveda Corporation <i>Bixa orellana</i> Project, Brazil 281
9.10.2	Cohune oil: marketing a personal care product for community development and conservation in Guatemala – an overview of the Conservation International and Croda Inc partnership 287
9.11	Conclusion 292
<b>10</b>	<b>Industry and the CBD 293</b>
10.1	Introduction 293
10.2	Companies' awareness and understanding of the CBD 295
10.3	Companies' opinions of the CBD 296
10.3.1	Positive views on the CBD 296
10.3.2	Negative views on the CBD 297
10.4	The impact of the CBD on business, and companies' response 300
10.4.1	Decrease in and consolidation of collecting activities 300
10.4.2	Greater recourse to <i>ex situ</i> collections 302
10.4.3	The increasing importance of intermediaries 302
10.4.4	Increased use of MTAs and emphasis on legal acquisition of samples 303
10.5	Corporate policies on access to genetic resources, traditional knowledge and benefit-sharing 303
10.5.1	Corporate policies addressing related environmental and social issues 308
10.5.2	Professional codes of conduct related to access to genetic resources, traditional knowledge and benefit-sharing 309
10.6	Institutional policies in response to the CBD 309
10.7	Conclusions 312
<b>11</b>	<b>Conclusions 313</b>
11.1	Overview 313
11.2	Introduction 313
11.3	Markets for natural products 315
11.4	The nature and extent of private-sector demand for access to genetic resources 316
11.4.1	Scientific and technological advances 316
11.4.2	Legal and policy environment 317
11.4.3	Demand for access to traditional knowledge 318
11.5	The nature and extent of benefit-sharing across industry sectors 319

## THE COMMERCIAL USE OF BIODIVERSITY

- 11.5.1 Pharmaceuticals 319
- 11.6 The role of intermediaries 322
- 11.7 Views on the CBD, and corporate and institutional policies 322
- 11.8 Access and benefit-sharing, sustainable development, and the conservation of biodiversity 323
- 12 Recommendations 325**
  - 12.1 Overview 325
  - 12.2 Recommendations to governments on access regulations 325
  - 12.3 Recommendations on the role of intermediary organisations 328
  - 12.4 Recommendations to industry 328
  - 12.5 Indicators of fair and equitable benefit-sharing 330
    - 12.5.1 Process indicators 330
    - 12.5.2 Content indicators 330
  - 12.6 Corporate and institutional policies on access and benefit-sharing 331
  - 12.7 Summary of recommendations 332
    - 12.7.1 Recommendations for governments regulating access 332
    - 12.7.2 Recommendations for companies and other organisations seeking access 332
- Appendix A The Influence of Natural Products on 1997 Pharmaceutical Sales Figures 333**
- Appendix B Scientific and Common Names of Selected Botanical Medicines 336**

## Appendix C Regulatory Frameworks for Botanical Medicines 337

- C.1 The EU 337
- C.2 Germany 337
- C.3 Japan 338
- C.4 The USA 338
- C.5 The WHO 339

## Appendix D Tentative List of Crops Under Negotiation as the Scope of the Multilateral System in the Revised International Undertaking 340

## Appendix E Regulatory Frameworks Relevant to the Release of Crop Varieties 341

- E.1 Seed certification 341
  - E.1.1 International certification and seed testing schemes 341
- E.2 Regulation of the release of GMOs 342
- E.3 Plant variety rights 345

## Useful Contacts and Sources of Information 347

## Glossary 356

## Bibliography 364

## Research Methodology and Team 384

## Index 391